$581.8M in CY2024 Part D spend156K claims · 26K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Glatiramer used for?
Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease,....
Is there a generic for Glatiramer?
Yes. 12 ANDAs filed at FDA, 6 generic manufacturers currently shipping.
How much does my plan pay for Glatiramer?
Across 329 Part D plans, Glatiramer averages $136.16/unit (NADAC). Lowest available: $43.75/unit. Highest in distribution: $541.74/unit.
Is Glatiramer on the FDA shortage list?
No. Glatiramer is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (10 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.